Merck shells out US$10bil in bid to diversify


The acquisition eases pressure on Merck to replace that revenue but does not eliminate the need for further deals. — Reuters

NEW YORK: Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug Keytruda.

Merck is set to lose revenue from Keytruda, the world’s top-selling drug with nearly US$30bil in annual sales, as key patents begin to expire in 2028.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

MPOB: Malaysian palm oil industry well-positioned for EUDR compliance
Is Malaysia's AI boom at risk?
SC unveils Sukuk PRISMA
99 Speed Mart cautiously optimistic on resilient demand for essentials
CIMB Islamic targets doubling of Islamic wealth assets by 2030
Big Caring Group posts RM72.52mil net profit ahead of Bursa listing
Citaglobal completes Perak hydropower acquisitions, strengthening power generation in its new energy business
TWL Holdings proposes RM26mil acquisition of Wisma TWL
Dialog remains focused on long-term strategies amid global uncertainties
Yes Group IPO public portion subscribed 2.80 times ahead of ACE Market debut

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read